Exclusive Summary

• - No core patent barriers remain; Pulmicort Respules (AstraZeneca) IP expired years ago and generics are available across major markets.
• - The 0.5 mg/2 mL and 1 mg/2 mL strengths match global mainstream dosing, covering pediatric and acute-setting needs.
• - ICS is first-line maintenance therapy for asthma; budesonide is on the WHO Essential Medicines List and endorsed by GINA, ensuring steady hospital and community demand.
• - Filing plans in the Philippines/Malaysia (Jul 2025) and the EU (Mar 2026) support rapid Distribution rollout in SEA and Europe.
• - Versus originator, typical markets see ~50–80% price reductions, enabling tender wins and out-of-pocket uptake.